金城医药：米拉贝隆取得化学原料药上市申请批准

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) has received approval from the National Medical Products Administration for its chemical raw material drug, Mirabegron, which is a selective β-3 adrenergic receptor agonist used to treat overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Group 1 - The company’s wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., is responsible for the approval of Mirabegron [1] - Mirabegron is specifically indicated for the treatment of overactive bladder (OAB) [1] - The approval marks a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [1]